Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Cut to $6.00 by Analysts at Leerink Partners

Recursion Pharmaceuticals (NASDAQ:RXRX) had its target price decreased by Leerink Partners from $7.00 to $6.00 in a research note released on Friday morning,Benzinga reports. Leerink Partners currently has a market perform rating on the stock.

Other equities analysts have also recently issued reports about the company. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Finally, KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $7.51 on Friday. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -4.91 and a beta of 0.86. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 1-year low of $5.60 and a 1-year high of $14.12. The stock’s 50-day moving average is $7.72 and its 200 day moving average is $7.08.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s quarterly revenue was down 57.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.42) earnings per share. On average, sell-side analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after purchasing an additional 9,737,196 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of Recursion Pharmaceuticals by 16.4% during the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after buying an additional 4,626,268 shares during the period. Softbank Group CORP. purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $99,152,000. State Street Corp increased its stake in shares of Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after buying an additional 4,120,685 shares during the period. Finally, Novo Holdings A S purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $68,375,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.